Paul Nguyen (Brigham and Women’s) led a study that suggests men who take hormone therapy for prostate cancer may have a higher risk of depression than patients who receive different treatment for these malignancies.
Patients diagnosed with chronic lymphocytic leukemia who have a specific gene mutation typically don’t survive longer than three years, but a drug approved Monday, based on science out of Dana-Farber, could change that. Matthew Davids (Dana-Farber) is quoted.
Pieter Cohen (Cambridge Health Alliance) led a study which found that a stimulant banned from international athletic competition has been detected in 14 easy-to-buy supplements.
Marcia Angell (HMS) authored this opinion piece on the evolution of the New England Journal of Medicine’s conflict-of-interest policies in medical research and the possible reasons for them.
Jonathan Hausmann (Boston Children’s) and John Brownstein (Boston Children’s) are researching a new way to diagnose a fever called ‘feverprints,’ associated with different illnesses to help doctors make quicker and more accurate diagnoses.
Isaac Kohane (HMS) participated in an interview about Daniel MacArthur’s (Mass General) study on people who remain healthy even though they carry genetic variants known to cause severe Mendelian childhood diseases.
The Drug Enforcement Agency announced last week that it is reviewing the possibility of reclassifying marijuana as a Schedule II drug, which would put it in the same category as Ritalin, Adderall and oxycodone. Kevin Hill (McLean) is quoted.
This article discusses the potential benefits and risks associated with the possibility of human gene editing. George Church (HMS) authored one response.
